Skip to main content
SpringerLink
Log in

Abaloparatide more cost effective than teriparatide

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2017 US dollars

Reference

  • Le QA, et al. Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States. Annals of Pharmacotherapy : 30 Aug 2018. Available from: URL: http://doi.org/10.1177/1060028018798034

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abaloparatide more cost effective than teriparatide. PharmacoEcon Outcomes News 812, 4 (2018). https://doi.org/10.1007/s40274-018-5271-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5271-x

Search

Navigation